HCPCS Level II code J7312 denotes a dexamethasone intravitreal implant, 0.1 mg, administered via injection into the vitreous cavity. This ophthalmic drug delivery modality is important for targeted intraocular corticosteroid therapy and has implications for specialty drug billing, site-of-service policies, and coverage determinations across national payers. The code is used to identify the specific drug product and dose for claims processing and utilization monitoring.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for intravitreal dexamethasone implants, payer coverage patterns and coding considerations, common modifiers applicable to drug and procedure billing, and benchmarks where available. The publication also highlights policy items that affect reimbursement and prior authorization practices for intravitreal corticosteroid implants.

This summary provides clinicians, billing professionals, and policy analysts with the essentials needed to recognize when J7312 applies, how site-of-service influences claim submission, and what to expect from major national payers. Data not available in the input will be noted in the relevant sections of the full publication.